Abcam, ab246535, Human PEDF ELISA Kit

Size: 1 x 96Tests / 10 x 96Tests
Human PEDF ELISA Kit is a single-wash 90-min Simplestep used to quantify Human PEDF with a sensitivity of 146 pg/mL. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Different formats for different needs: 10x96 plates for bulk orders
Key facts
Detection method:Colorimetric,
Sample types:Citrate plasma, Cell culture supernatant, Serum,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 146 pg/mL,
Range:468.75 - 30000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human PEDF ELISA Kit ab246535 is a rapid single-wash 90-min Sandwich ELISA to measure Human PEDF in cell culture supernatant, citrate plasma, serum. This SimpleStep sensitivity is 146 pg/mL.
How the assay works
Human PEDF SimpleStep ELISA
employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA
plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA
protocol summary in the image section for further details.
Assay Specificity
Our SimpleStep ELISA
kits use recombinant monoclonal antibodies rigorously validated to ensure the highest level of consistency and reproducibility, improved sensitivity and specificity and ease of scalability and security of supply.
Please refer to our protocol booklet for more details.
Human PEDF ELISA Kit ab246535 protocol summary
1. Mix: add samples/standards to the wells together with the capture and detector antibody cocktail. Incubate 1 hr at room temperature
2. Wash
3. Add TMB development solution - incubate for 10 min
4. Add Stop solution
5. Read the results on a plate reader at 450 nm
Design your own immunoassay
We offer the antibody pair used in this kit in a BSA and Azide-free format, ready for conjugation:
- Anti-PEDF antibody [EPR21067-285] - BSA and Azide free (Capture)
ab259608
- Anti-PEDF antibody [EPR21067-2] - BSA and Azide free (Detector)
ab259608

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PEDF also known as pigment epithelium-derived factor is a secreted glycoprotein with a mass of approximately 50 kDa. Its expression is highest in the retina and also occurs in several other tissues including liver and brain. PEDF has neurotrophic and neuroprotective properties. The PEDF protein works mechanically by interacting with receptors on cell surfaces to inhibit angiogenesis and promote neuronal survival and differentiation.
Biological function summary
PEDF plays a significant role in controlling angiogenesis due to its ability to inhibit excessive blood vessel formation. This makes PEDF essential in balancing the vasculature and nutrient availability in tissues. While PEDF does not form part of a larger protein complex its activity influences the biological interplay between cells by stabilizing the extracellular matrix and influencing cell signaling pathways involved in maintaining tissue homeostasis.
Pathways
PEDF interacts directly within the angiogenesis and neuroprotection pathways influencing cellular processes critical for normal tissue function. In angiogenesis PEDF disrupts the VEGF pathway by serving as an inhibitor thereby restricting uncontrolled vessel growth. It also plays a role in neuroprotection pathways where it cooperates with proteins like nerve growth factor to enhance neuronal survival and repair processes.
PEDF relates significantly to diabetic retinopathy and cancer. PEDF's angiogenesis inhibition has therapeutic implications in diabetic retinopathy where unregulated blood vessel growth leads to vision loss. It also shows potential in cancer therapy by targeting tumor angiogenesis. In both conditions its interaction with VEGF is notable as it competes to modulate angiogenesis with potential consequences for disease progression and treatment strategies.